Landmark 188 · Trial in people
NEU-411 (NEULARK)
Will tell us whether blocking LRRK2 helps when people are picked by a test, not only by diagnosis. It uses a phone-app score at one year.
In short
After BIIB122 failed in unselected early Parkinson's, Neuron23's 150-person Phase 2 gives a second LRRK2 inhibitor only to people whose disease a companion test flags as LRRK2-driven; the main phase is due to finish around December 2027.
- What it is
- Trial in people
- Outcome
- Result due Dec 2027
- When
- 2025–2027
- Size
- 150 people · Phase 2
- Approach
- Treat the inherited causes
- Research lane
- LRRK2
- Trial registry
- NCT06680830
- Last checked
- 18 Oct 2026
The research record
This is the project's file for this landmark, as written and checked. Sources are listed at the end; anything not yet confirmed is marked "Not yet verified".
Who
Neuron23 (US). Registry: NCT06680830. Started 17 January 2025; recruiting, status last verified August 2026.
What is being tested
LRRK2 is the gene that landmark 7 tied to Parkinson's. The large LUMA trial (landmark 145) found that a LRRK2 inhibitor hit its target yet did not slow people picked only by diagnosis. NEULARK bets that the answer depends on who is treated.
- About 150 adults with early Parkinson's, picked with an investigational companion diagnostic test. Neuron23 says up to 30% of people have LRRK2-driven disease (company claim; I did not verify it).
- NEU-411 30 mg once daily or placebo, 1:1, for 52 weeks, then an optional 26-week open-label extension.
- Phase 2, fully masked.
What would count as success
The main measure is the change in a digital score from Roche's Parkinson's smartphone app (v3.0) at 52 weeks versus placebo, plus safety. Registry estimates: primary completion December 2027, completion June 2028. Neuron23 guides to top-line data in 2027. A positive result would show that selecting patients by LRRK2 biology rescues the approach; a negative one would add to LUMA.
Sources
- ClinicalTrials.gov NCT06680830 (read via API, 18 Oct 2026)
- Neuron23 release, 19 Nov 2024 (Business Wire) · Precision Medicine Online
- Not yet verified: what the companion test measures (carrier status versus pathway biomarkers); enrolment progress; how the digital endpoint was validated.
How it connects
Built on
- tests The LRRK2 gene: the first gene-based drug target · 2004
- responds to BIIB122 / DNL151 (LUMA) · 2026
Led to
None recorded.